Skip to main content

New top story from Time: FDA Panel Greenlights First Single-Shot COVID-19 Vaccine, from Johnson & Johnson

https://ift.tt/3pZf3dk

The U.S. Food and Drug Administration’s (FDA) vaccine advisory committee earlier today (Feb. 26) voted unanimously to recommend Johnson & Johnson’s COVID-19 vaccine for emergency use authorization. While the FDA isn’t obligated to follow the committee’s advice, it generally does.

At the end of a full day of review and discussion of the company’s shot, all 22 voting members of the committee agreed that the vaccine was safe and effective enough to be used by the public. It’s the third vaccine that the group of independent experts has recommended, following Pfizer-BioNTech and Moderna. Unlike the two previous vaccines, J&J’s is a single shot, and can be shipped and stored under refrigerated, not frozen conditions, as the other two require.

The single dosing played a part in the committee’s decision. Logistically, vaccinating people one time is much easier than asking them to return for a second dose. “This was a relatively easy call,” Dr. Eric Rubin, editor in chief of the New England Journal of Medicine and professor at Harvard T.H. Chan School of Public Health, who voted to recommend the shot said during the discussion. “[The vaccine] clearly gets way over the bar of safety and efficacy, and it’s a single-dose vaccine.”

The committee members reviewed data presented by Janssen Pharmaceuticals, the J&J arm that developed the vaccine, as well as FDA scientists’ review of that data. Janssen’s vaccine uses a different technology than Pfizer-BioNTech and Moderna, which both relied on a new platform involving mRNA. Janssen’s vaccine, on the other hand, is made with a weakened cold virus that can’t cause disease, manipulated so that it carries the genes for making one of the key proteins of SARS-CoV-2, the virus that causes COVID-19. Once that viral protein is introduced to the body, human immune cells learn to recognize it as foreign and launch attacks against it.

In Janssen’s primary vaccine study, involving nearly 44,000 people, a single dose was found to be 66% effective in protecting people from moderate to severe COVID-19 disease. It was slightly less effective in protecting against new variants of the virus—against one that was first identified in South Africa, it was around 57%. Still, that protection met the threshold of 50% efficacy set by the FDA for granting emergency use authorization.

Committee members raised questions about how much of the immune response to the COVID-19 virus might be blunted by a response mounted against the weakened cold virus used as the delivery vessel, a well known effect using this vaccine platform. Such vaccines are also potentially less effective when boosted with additional shots since the body becomes tolerant to the weakened virus vector. However, Dr. Johan Van Hoof, managing director of Janssen Vaccines and Prevention, noted that tests on the company’s HIV vaccine candidate using similar technology have shown that people boosted with additional shots years after the first continued to generate strong immune responses that didn’t seem to be significantly affected by the weakened virus vector.

Many committee members raised questions about the company’s data showing that the vaccine produced a slightly lower response in terms of antibody levels against the virus among people over age 60, especially those with underlying health conditions—a group particularly vulnerable to COVID-19. However, Janssen studies found that these people still did not develop severe COVID-19 disease or need hospitalization compared to people getting placebo. In fact, the vaccine was 85% effective in protecting people from severe disease and overall there were only 21 deaths among the 44,000 people studied; five occurring among those who were vaccinated and the remainder among the placebo group. None of the deaths were considered related to the vaccine.

The FDA scientists did note in their review that some participants in the study did experience serious side effects, including tinnitus (ringing in the ears), clotting and hives—which could be related to the vaccine and are worth further follow up. However, these were rare, and overall the vaccine was safe with most who reported side effects having only mild to moderate reactions including headache, chills and muscle aches.

The other question that continued to pop up during the day-long discussion focused on whether Janssen’s vaccine is really a one-shot vaccine or whether it, like the Pfizer-BioNTech and Moderna vaccines, actually requires a two-shot regimen. While the data the company submitted were from a trial in which participants were given only a single dose, the company is currently conducting another study of 30,000 people who will receive two doses of the shot—to see if an additional booster will raise immune responses even further.

If two doses prove to be more effective, it will raise a tricky question about what to do with people who might receive the single dose shot in coming weeks or months, should the one-dose regimen be authorized. Van Hoof argues that this is a question worth putting off for later, given the urgency of the current situation. “We feel the results of the study of our single dose showed high efficacy against severe disease, especially hospitalizations and death, and in a situation of mass vaccination programs, our regimen is extremely well positioned to be used during the outbreak,” he said.

Then of course there is the question of the recently identified genetic variants of SARS-CoV-2 that appear even more infectious than the original virus. Pfizer-BioNTech and Moderna did not have to deal with that when they submitted their requests back in December 2020, but the companies have since conducted additional tests that have shown that their vaccines remain effective in protecting against the major new mutations. Janssen’s submission to the FDA included some early data on the efficacy of its vaccine against the new variants, and Van Hoof told the committee that the company plans to continue genetic sequencing virus from people in the company’s trials if they test positive and will include that information in the final request for full approval which could come later this year. In the meanwhile, Janssen—like Pfizer-BioNtech and Moderna—is already working on a next-generation vaccine specifically targeting the new variants that could begin human testing by summer.

The FDA committee’s decision to recommend the Janssen shot now goes to the agency. If the FDA agrees to grant the emergency use authorization, the next step will be for the Centers for Disease Control and Prevention’s immunization committee to work out details of who should be vaccinated with the new shot, and the logistics for how to make that happen. That CDC committee will also likely make decisions about whether certain groups should be targeted to receive this specific vaccine, and what advice to provide vaccinators when people ask about whether they will need a second shot. That information won’t be available until Janssen completes its two-dose study in coming months.

Comments

Popular posts from this blog

FOX NEWS: Cincinnati zoo renames sloth habitat after late 1-year-old who loved sloths The sloth habitat at Ohio's Cincinnati Zoo will be named after a toddler who recently passed away.

Cincinnati zoo renames sloth habitat after late 1-year-old who loved sloths The sloth habitat at Ohio's Cincinnati Zoo will be named after a toddler who recently passed away. via FOX NEWS https://ift.tt/3DLAshi

L Taraval Improvement Project Update

L Taraval Improvement Project Update By Sevilla Mann Roundtable at the Community Parklet Shares Project Updates  This past week, the SFMTA hosted a media roundtable discussing updates about the L Taraval Improvement Project at the community parklet located in front of the The Rolling Out Café  on Taraval St.   Segment B construction began in February 2022 and is scheduled to be completed Fall 2024. Sewer and water infrastructure work is currently taking place. Future work includes track work, overhead line work, the construction of new boarding islands and streetscape improvements.    On hand to answer questions and provide updates was District Four Supervisor Gordon Mar, SFMTA Board Director Sharon Lai and Director of Transportation Jefferey Tumlin.   The Roundtable  Supervisor Mar opened the discussion by highlighting the many benefits that the local community will receive with the planned infrastructure upgrades along the corridor. These benefits include:   Replacing sew

Traffic Collisions have Decreased on San Francisco’s Slow Streets

Traffic Collisions have Decreased on San Francisco’s Slow Streets By Julia Malmo   As a whole, Slow Streets are safer than they were before being designated Slow Streets  Streets that are part of the SFMTA’s  Slow Streets Program have become measurably safer since the program began in 2020, with the number of traffic crashes falling by almost half. On average, these corridors have seen a 48% drop in collisions following their designation as Slow Streets, compared with a 14% drop in collisions citywide over the same period. Slow Streets also are more welcoming for people who walk, bike and roll. Fewer than 1,000 vehicles per day use all but four of the current Slow Streets (20th Street, Minnesota Street, Noe Street, and Page Street).  The goal of the program is to create safe, shared streets that are comfortable and enjoyable for people of all ages and abilities, using any mode of transportation. We now can see how it’s doing in a new evaluation report . When the SFMTA Board appr

IPL 2020 | KKR, SRH search for first win to get off the mark https://ift.tt/333a9nc

Having suffered defeats in their opening games, the Kolkata Knight Riders and Sunrisers Hyderabad will lock horns on Saturday at the Sheikh Zayed Stadium in Abu Dhabi. While Kolkata faced a tough 49-run loss to defending champions Mumbai Indians, the Sunrisers suffered a monumental batting collapse against Royal Challengers Bangalore, losing the game by 10 runs.

https://ift.tt/eA8V8J कोरोना सकंट में TV सीरियल की शूटिंग शूरू, मास्क लगाकर पहुंचे स्टार्स- निया, पार्थ से लेकर रश्मि-PICS

कोरोना वायरस के चलते जारी लॉकडाउन में टीवी व फिल्मों की शूटिंग बंद थी। कोरोना के खतरे को देखते हुए तमाम सीरियल की शूटिंग रोक दी गई तो वहीं फिल्मों को रिलीज अटक गई। एंटरटेंमेंट इंडस्ट्री को कोरोना के चलते करोड़ों from टेलीविजन की खबरें | Television News in Hindi | TV Serials Update in Hindi – FilmiBeat Hindi http:/hindi.filmibeat.com/television/tv-shooting-starts-kasauti-zindagi-kay-naagin-nia-sharma-parth-samthaan-rashmi-desai-pics-090604.html?utm_source=/rss/filmibeat-hindi-television-fb.xml&utm_medium=23.11.231.156&utm_campaign=client-rss

Women Pioneers at Muni: Adeline Svendsen and Muni’s First Newsletter

Women Pioneers at Muni: Adeline Svendsen and Muni’s First Newsletter By Jeremy Menzies To close out Women’s History Month, here’s a look back at one woman whose work to bring Muni staff together in the late 1940s created a legacy that lives on to this day. Adeline “Addy” Svendsen was founding editor of Muni’s first internal newsletter, “ Trolley Topics .” Adeline Svendsen sits at her desk in the Geneva Carhouse office building in this 1949 shot. Trolley Topics was a new venture when it started in February 1946. As Svendsen wrote in the first issue it was created, “to bring a little fun, a little news, and a lot of good will to all our fellow employees in the Railway.” Just two years prior in 1944, Muni merged with the Market Street Railway Company, expanding the small municipal operation into the largest transit provider in the city with hundreds of employees, vehicles of every shape and size, and dozens of facilities scattered across town. The newsletter was meant to help unite

FOX NEWS: Decadent double chocolate mint cookies for National Chocolate Day National Chocolate Day on Oct. 28th calls for a serious dose of chocolate.

Decadent double chocolate mint cookies for National Chocolate Day National Chocolate Day on Oct. 28th calls for a serious dose of chocolate. via FOX NEWS https://ift.tt/3nEJxSB

New top story from Time: Summer Tutoring Is Not the Solution to a Lost Year of Schooling. It Might Hurt Kids More Than It Helps Them

https://ift.tt/2Wpnci1 Summer tutoring has become the rallying cry by politicians and pundits as a way to address the learning loss from months of remote and hybrid learning. A frightening number of students did not show up to class last school year, including up to 15% of kindergarteners in some school districts. But tutoring is the not the easy solution many think it is. Before parents sign up their children, they need to do their own homework and, except under specific conditions, they should not pursue tutoring. Simply put, most children do not benefit long term from standard tutoring. Moreover, current trends in supplemental education can end up hurting children. [time-brightcove not-tgx=”true”] Tutoring can work well under certain conditions for children. Unfortunately, those conditions are quite strict. First, tutors should have a strong command of the content and must find ways to connect it to the student’s interests. Second, tutoring is more effective when

New top story from Time: The Ballroom Scene Has Long Offered Radical Freedoms For Black and Brown Queer People. Today, That Matters More Than Ever

https://ift.tt/2O8qsKr Marginalized by prejudice, violence, housing insecurity, and HIV infection rates among other burdens, Black and brown transgender and gender-nonconforming people face particular challenges in establishing secure, nourishing communities—both within LGBTQ spaces and in society at large. One response to these stigmas has been the formation of self-sustaining social networks and cultural groups, such as the ballroom scene, a formidable social movement and creative collective for LGBT people of color. Amid what has been called a new golden age for Black culture and storytelling , a particular “Renaissance” in queer Black art and cultural representation is clear. Ballroom culture is now widely seen and celebrated (and appropriated) in the mainstream—across fashion campaigns, music videos, social media and in TV shows like Pose , Legendary , and RuPaul’s Drag Race . And i n this moment, ballroom and voguing as the body politic has much to teach the world abou

New Dashboards Give a Window into Muni Service Changes

New Dashboards Give a Window into Muni Service Changes By Kate McCarthy An inspector manages Muni service. New dashboards that help inform changes to Muni service are now live at SFMTA.com/MuniData Many factors inform our decisions about Muni service adjustments. These include making sure changes to service support the SFMTA’s values, which are economic vitality, environmental stewardship, trust and equity. We also evaluate travel patterns. You can now explore these patterns using the new Muni data dashboards  (SFMTA.com/MuniData). When looking at possible Muni service changes, the first thing we do is turn to the Muni Service Equity Strategy for guidance. Using the Muni Service Equity Strategy, we prioritize providing Muni service along routes that more often serve people of color, members of low-income households, and/or those who are dependent upon transit service, including people with disabilities and seniors. We also use ridership data to analyze where riders are boardin